Products for Research Use Only

SID 26681509

CAT: 0804-HY-103353-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-103353-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
SID 26681509 is a potent, reversible, competitive, and selective inhibitor of human cathepsin L with an IC50 of 56 nM. SID 26681509 inhibits in vitro propagation of malaria parasite Plasmodium falciparum and inhibits Leishmania major with IC50s of 15.4 μM and 12.5 μM, respectively. SID 26681509 shows no inhibitory activity against cathepsin G[1].
CAS Number
958772-66-2
UNSPSC
12352005
Target
Cathepsin; Parasite
Type
Reference compound
Related Pathways
Anti-infection; Metabolic Enzyme/Protease
Applications
Neuroscience-Neuromodulation
Field of Research
Cancer; Infection
Assay Protocol
https://www.medchemexpress.com/sid-26681509.html
Purity
99.16
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C(NNC(SCC(NC1=CC=CC=C1CC)=O)=O)[C@H](CC2=CNC3=CC=CC=C23)NC(OC(C)(C)C)=O
Molecular Formula
C27H33N5O5S
Molecular Weight
539.65
References & Citations
[1]Shah PP, et al. Kinetic characterization and molecular docking of a novel, potent, and selective slow-binding inhibitor of human cathepsin L. Mol Pharmacol. 2008 Jul;74 (1) :34-41.|[2]Pribis JP, et al. The HIV Protease Inhibitor Saquinavir Inhibits HMGB1-Driven Inflammation by Targeting the Interaction of Cathepsin V with TLR4/MyD88. Mol Med. 2015 Dec;21 (1) :749-757.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Cathepsin L; Leishmania; Plasmodium
Citation 01
IScience. 2024 Oct 4;27 (11) :111024.|Nat Commun. 2020 Mar 27;11 (1) :1620.|Nat Commun. 2022 May 26;13 (1) :2935.|Signal Transduct Target Ther. 2021 Mar 27;6 (1) :134.|Signal Transduct Target Ther. 2023 Oct 11;8 (1) :390.